Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants.
Administration, Oral
Adult
Antibodies, Antiphospholipid
/ therapeutic use
Anticoagulants
/ therapeutic use
Antiphospholipid Syndrome
/ drug therapy
Blood Coagulation
/ drug effects
Blood Coagulation Tests
/ methods
Dabigatran
/ therapeutic use
Female
Humans
Lupus Coagulation Inhibitor
/ therapeutic use
Male
Middle Aged
Partial Thromboplastin Time
/ methods
Prothrombin Time
/ methods
Pyrazoles
/ therapeutic use
Pyridones
/ therapeutic use
Retrospective Studies
Rivaroxaban
/ therapeutic use
Thrombophilia
/ drug therapy
Thrombosis
/ drug therapy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 07 2020
22 07 2020
Historique:
received:
08
03
2020
accepted:
08
07
2020
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Functional tests for lupus anticoagulants (LA) as part of a thrombophilia workup are commonly performed in patients under anticoagulant therapy that may interfere with assay results. There is no consensus on how these tests should be assessed in patients on direct oral anticoagulants (DOACs). In this retrospective cohort study, we analysed data from patients with a history of thrombosis in whom dilute Russell viper venom time (dRVVT), LA-sensitive aPTT, and solid phase assays for antiphospholipid antibodies (aPL) were performed (n = 3,147, thereof 588 on rivaroxaban, 144 on apixaban, 1,179 on other anticoagulant drugs). The dRVVT ratio was correlated with rivaroxaban (r = 0.30, P < 10
Identifiants
pubmed: 32699227
doi: 10.1038/s41598-020-69199-1
pii: 10.1038/s41598-020-69199-1
pmc: PMC7376154
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Anticoagulants
0
Lupus Coagulation Inhibitor
0
Pyrazoles
0
Pyridones
0
apixaban
3Z9Y7UWC1J
Rivaroxaban
9NDF7JZ4M3
Dabigatran
I0VM4M70GC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12221Références
Chaturvedi, S. & McCrae, K. R. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 31, 406–417 (2017).
doi: 10.1016/j.blre.2017.07.006
Andreoli, L. et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature. Arthritis Care Res. 65, 1869–1873 (2013).
doi: 10.1002/acr.22066
Connors, J. M. Thrombophilia testing and venous thrombosis. N. Engl. J. Med. 377, 1177–1187 (2017).
doi: 10.1056/NEJMra1700365
Miyakis, S. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4, 295–306 (2006).
doi: 10.1111/j.1538-7836.2006.01753.x
Wilson, W. A. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum. 42, 1309–1311 (1999).
doi: 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
Moore, G. W. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin. Thromb. Haemost. 40, 163–171 (2014).
doi: 10.1055/s-0033-1364185
Galli, M., Luciani, D., Bertolini, G. & Barbui, T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood 101, 1827–1832 (2003).
doi: 10.1182/blood-2002-02-0441
Galli, M. Antiphospholipid syndrome: Association between laboratory tests and clinical practice. Pathophysiol. Haemost. Thromb. 33, 249–255 (2003).
doi: 10.1159/000083810
Ruffatti, A. et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb. Haemost. 96, 337–341 (2006).
doi: 10.1160/TH06-05-0287
Galli, M. & Barbui, T. Antiphospholipid antibodies and thrombosis: Strength of association. Hematol. J. 4, 180–186 (2003).
doi: 10.1038/sj.thj.6200206
Brandt, J. T., Triplett, D. A., Alving, B. & Scharrer, I. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcomittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation of the ISTH. Thromb. Haemost. 74, 1185–1190 (1995).
doi: 10.1055/s-0038-1649901
Pengo, V. et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the Internation Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 7, 1737–1740 (2009).
doi: 10.1111/j.1538-7836.2009.03555.x
Keeling, D. et al. Guidelines on the investigation and management of antiphospholipid syndrome. Br. J. Haematol. 157, 47–58 (2012).
doi: 10.1111/j.1365-2141.2012.09037.x
Merriman, E. et al. Rivaroxaban and false positive lupus anticoagulant testing. Thromb. Haemost. 105, 385–386 (2011).
doi: 10.1160/TH10-08-0511
Mani, H., Hesse, C., Stratmann, G. & Lindhoff-Last, E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb. Haemost. 109, 127–136 (2013).
doi: 10.1160/TH12-04-0228
van Os, G. M., de Laat, B., Kamphuisen, P. W., Meijers, J. C. & de Groot, P. G. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J. Thromb. Haemost. 9, 1657–1659 (2011).
doi: 10.1111/j.1538-7836.2011.04395.x
Bonar, R. et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: A comprehensive assessment using in vitro and ex vivo samples. Pathology 48, 60–71 (2016).
doi: 10.1016/j.pathol.2015.11.025
Bonar, R. et al. The effect of dabigatran on haemostasis tests: A comprehensive assessment using in vitro and ex vivo samples. Pathology 47, 355–364 (2015).
doi: 10.1097/PAT.0000000000000252
Góralczyk, T., Iwaniec, T., Wypasek, E. & Undas, A. False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome. Blood Coagul. Fibrinolysis 13, 1264–1273 (2015).
Martinuzzo, M. E. et al. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int. J. Lab. Hematol. 36, 144–150 (2014).
doi: 10.1111/ijlh.12138
Arachchillage, D. R. et al. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J. Thromb. Haemost. 13, 1264–1273 (2015).
doi: 10.1111/jth.12917
Hillarp, A. et al. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays. Scand. J. Clin. Lab. Investig. 78, 575–583 (2018).
doi: 10.1080/00365513.2018.1522664
Hillarp, A. et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J. Thromb. Haemost. 12, 1545–1553 (2014).
doi: 10.1111/jth.12649
Douxfils, J. et al. Laboratory testing in patients treated with direct oral anticoagulants: A practical guide for clinicians. J. Thromb. Haemost. 16, 209–219 (2018).
doi: 10.1111/jth.13912
Murer, L. M., Pirruccello, S. J. & Koepsell, S. A. Rivaroxaban therapy, false-positive lupus anticoagulant screening results, and confirmatory assay results. Lab. Med. 47, 275–278 (2016).
doi: 10.1093/labmed/lmw029
Ratzinger, F. et al. Lupus-anticoagulant testing at NOAC trough levels. Thromb. Haemost. 116, 235–240 (2016).
doi: 10.1160/TH16-02-0081
Antovic, A. et al. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. Thromb. Haemost. 117, 1700–1704 (2017).
doi: 10.1160/TH17-03-0204
Kim, P. Y. et al. Mechanistic basis for the differential effects of rivaroxaban and apixaban on global tests of coagulation. T. H. Open 2, e190–e201. https://doi.org/10.1055/s-0038-1649507 (2018).
doi: 10.1055/s-0038-1649507
Triplett, D. A. & Brandt, J. Laboratory identification of the lupus anticoagulant. Br. J. Haematol. 73, 139–142 (1989).
doi: 10.1111/j.1365-2141.1989.tb00242.x